viral
infect
remain
major
caus
human
diseas
mortal
novel
infecti
agent
period
transmit
human
speci
may
becom
establish
human
popul
strauss
strauss
possibl
control
mani
seriou
human
diseas
smallpox
poliomyel
yellow
fever
tickborn
enceph
japanes
b
enceph
hepat
b
well
common
viral
infect
children
mump
measl
chicken
pox
rubella
safe
effect
vaccin
influenza
viru
vaccin
also
reason
effect
provid
vaccin
made
circul
viru
strain
howev
mani
viru
infect
current
prevent
vaccin
includ
chronic
infect
may
difficult
target
immun
system
human
immunodefici
viru
hiv
hepat
c
viru
hcv
papillomavirus
infect
common
develop
countri
dengu
hepat
e
infect
newli
discov
spread
new
area
west
nile
viru
sever
acut
respiratori
syndrom
sar
viru
common
respiratori
infect
caus
rhinovirus
well
viru
group
import
health
econom
burden
sinc
rhinovirus
alon
includ
hundr
differ
serotyp
infect
prevent
vaccin
review
sever
viru
group
target
antivir
drug
tabl
howev
clear
antivir
arsen
remain
inadequ
mani
way
search
new
antivir
compound
strategi
continu
essenti
nevertheless
signific
progress
front
achiev
recent
year
may
surpris
sinc
postgenom
era
nucleotid
sequenc
entir
genom
determin
exist
mani
viru
group
two
decad
even
possibl
produc
purifi
crystal
viral
protein
allow
structurebas
approach
design
synthesi
new
antivir
drug
search
antivir
agent
crucial
depend
detail
understand
reaction
interact
occur
molecular
level
viral
infect
everi
essenti
step
viru
life
cycl
potenti
site
antivir
intervent
summar
tabl
virusencod
protein
target
attract
present
uninfect
cell
host
target
involv
viral
replic
also
consid
review
focu
recent
advanc
prospect
small
molecul
synthet
antivir
variou
group
rna
virus
consid
antibodi
antisens
oligonucleotid
ribozym
rna
interfer
gener
immunomodulatori
substanc
interferon
may
promis
instanc
antivir
agent
inhibit
herpesvirus
date
back
idoxuridin
idu
trifluorothymidin
tft
drug
toxic
side
effect
use
topic
adenin
arabinosid
ara
less
toxic
use
system
sever
herp
simplex
viru
infect
howev
breakthrough
made
acyclovir
acv
synthes
compound
phosphoryl
acvmonophosph
herp
viru
thymidin
kinas
follow
phosphoryl
acvtriphosph
cellular
kinas
whereaft
incorpor
dna
caus
chain
termin
acv
follow
improv
deriv
ganciclovir
penciclovir
famciclovir
valaciclovir
wider
applic
sever
herpesvirus
tabl
review
de
clercq
global
spread
hiv
epidem
continu
unab
hiv
may
consid
success
stori
antivir
drug
develop
formid
effort
transform
lethal
infect
diseas
control
extent
pomerantz
horn
viru
isol
first
specif
treatment
approv
zidovudin
also
known
azidothymidin
azt
inhibitor
viral
polymeras
call
revers
transcriptas
zidovudin
belong
drug
class
nucleosid
revers
transcript
inhibitor
nrti
addit
nrti
develop
sinc
number
nucleosid
nucleotid
analogu
approv
hiv
total
eight
recent
emtricitabin
tabl
fig
howev
soon
realiz
hiv
rapidli
becom
resist
zidovudin
compound
given
monotherapi
due
mutat
appear
revers
transcriptas
major
breakthrough
achiev
nonnucleosid
revers
transcriptas
inhibitor
nnrti
inhibitor
viral
proteas
approv
treatment
tabl
develop
led
preval
tripl
combin
therapi
commonli
includ
proteas
inhibitor
nnrti
togeth
two
nrti
howev
even
regimen
known
highli
activ
antiretrovir
therapi
complet
erad
hiv
bodi
residu
replic
viru
resist
drug
use
eventu
develop
problem
includ
consider
side
effect
caus
drug
well
larg
econom
burden
associ
combin
therapi
thu
consider
incent
develop
compound
fewer
side
effect
improv
efficaci
better
pharmacokinet
properti
recent
approv
proteas
inhibitor
atazanavir
taken
daili
appear
uniqu
resist
profil
compar
proteas
inhibitor
colonno
et
al
mean
virus
becom
resist
atazanavir
still
suscept
mani
proteas
inhibitor
furthermor
atazanavir
induc
chang
serum
lipid
level
sann
et
al
chang
lipid
metabol
signific
problem
associ
proteas
inhibitor
treatment
yet
anoth
proteas
inhibitor
tipranavir
phase
iii
clinic
trial
plosker
figgitt
tipranavir
first
efficaci
nonpeptid
inhibitor
hiv
proteas
fig
appear
improv
resist
profil
multipl
mutat
proteas
requir
high
level
resist
therefor
hiv
strain
resist
previous
develop
inhibitor
still
appear
suscept
tipranavir
larder
et
al
tipranavir
might
primarili
use
salvag
therapi
patient
proteas
inhibitor
fail
nnrti
class
capravirin
phase
iii
clinic
trial
may
activ
mutant
resist
nnrti
although
limit
peerreview
inform
avail
contrast
polymeras
proteas
inhibitor
compound
affect
third
enzym
encod
hiv
name
integras
still
rel
earli
develop
appear
specif
nontox
inhibitor
integras
difficult
develop
sinc
integras
share
properti
enzym
interact
nucleic
acid
substrat
howev
potent
compound
report
recent
hazuda
et
al
new
highli
promis
class
hiv
antivir
inhibitor
viral
entri
may
act
multipl
step
complex
cell
attach
fusion
pathway
hiv
moor
dom
first
entri
inhibitor
alreadi
approv
acid
synthet
peptid
known
enfuvirtid
matthew
et
al
ident
sequenc
portion
hiv
envelop
glycoprotein
act
form
complex
fusionactiv
conform
therebi
inhibit
fusion
viral
cellular
membran
due
chemic
natur
enfuvirtid
expens
manufactur
administ
frequent
inject
mani
agent
target
entri
process
develop
moor
dom
sever
small
molecul
compound
bind
hiv
coreceptor
prevent
hiv
use
protein
entri
process
first
known
schc
specif
target
strizki
et
al
fig
schc
subsequ
displac
anoth
compound
schd
coreceptor
use
hiv
strain
essenti
normal
develop
mice
suggest
may
block
without
major
side
effect
thu
mani
compani
target
promis
compound
includ
develop
pfizer
tabl
influenza
consid
mani
signific
viral
threat
human
annual
influenza
epidem
swipe
globe
occasion
new
virul
strain
caus
pandem
great
destruct
potenti
event
pandem
strain
may
imposs
manufactur
requir
quantiti
specif
vaccin
time
amantadin
rimantadin
avail
influenza
treatment
long
time
extens
use
due
side
effect
rapid
develop
resist
viru
influenza
virion
surfac
protein
hemagglutinin
bind
cell
surfac
neuramin
acid
viru
entri
neuraminidas
remov
neuramin
acid
residu
glycoprotein
allow
effici
viru
releas
long
time
major
focu
antiinfluenza
drug
develop
structur
known
sinc
earli
target
first
prefer
hemagglutinin
ha
howev
attempt
fail
due
unfavor
geometri
sialic
acid
bind
site
within
ha
protein
wade
contrast
neuraminidas
success
target
small
neuramin
acid
deriv
design
basi
protein
structur
von
itzstein
et
al
kim
et
al
compound
inhal
zanamivir
oral
administ
oseltamivir
approv
prophylact
therapeut
treatment
influenza
viru
infect
gubareva
et
al
even
optim
condit
two
drug
replac
vaccin
howev
offer
mean
allevi
seriou
symptom
influenza
prophylact
use
may
even
prevent
diseas
aoki
et
al
hayden
et
al
neuraminidas
inhibitor
togeth
amantadin
mean
put
rapidli
spread
new
pandem
influenza
infect
therefor
unnecessari
use
drug
restrict
minimum
avoid
creation
drugresist
influenza
viru
strain
gubareva
intracellular
phase
influenza
viru
life
cycl
also
present
sever
interest
target
addit
rnadepend
rna
polymeras
rdrp
possess
rna
virus
influenza
encod
uniqu
capdepend
endonucleas
enzym
cut
cellular
mrna
gener
short
nt
capcontain
primer
subsequ
util
polymeras
initi
rna
synthesi
endonucleas
inhibitor
effect
viru
describ
hast
et
al
park
et
al
virus
caus
signific
respiratori
infect
includ
positivestrand
rna
rhinovirus
coronavirus
well
respiratori
syncyti
viru
rsv
negativestrand
rna
viru
paramyxoviru
famili
interest
inhibitor
viru
fusion
describ
rsv
recent
identifi
compound
oral
bioavail
inhibit
viru
replic
mous
model
cianci
et
al
dougla
et
al
specul
rsv
fusion
protein
bind
sever
differ
class
small
molecul
fusion
process
attend
chang
protein
conform
provid
multipl
target
inhibit
togeth
success
target
hiv
fusion
protein
may
indic
viral
fusion
protein
gener
could
promis
target
drug
develop
see
also
plemper
et
al
differ
approach
treatment
paramyxoviru
infect
review
recent
saladino
et
al
result
recent
appear
sever
acut
respiratori
syndrom
sar
viru
coronavirus
attain
promin
posit
studi
antivir
strategi
previous
recognis
major
caus
mild
respiratori
infect
human
signific
need
treatment
within
year
recognit
sar
viru
sequenc
genom
sever
structur
viral
replicas
protein
alreadi
determin
inhibitor
studi
progress
coronaviru
genom
encod
sever
type
enzym
snijder
et
al
may
consid
potenti
target
inhibit
ribavirin
given
intraven
patient
suffer
sarscov
infect
outbreak
shown
ineffect
care
conduct
studi
sung
et
al
exist
drug
well
larg
compound
librari
screen
largescal
effort
find
inhibitor
sarscov
could
use
case
lethal
viru
reappear
wu
et
al
major
challeng
treatment
respiratori
infect
caus
agent
need
accur
rapidli
identifi
onset
symptom
infect
alreadi
progress
significantli
symptom
appear
antivir
treatment
must
initi
prophylact
immedi
appear
symptom
order
effect
factor
limit
use
current
antiinfluenza
viru
drug
gubareva
et
al
like
even
signific
handicap
treat
milder
respiratori
infect
consider
work
carri
inhibitor
rhinoviru
replic
tabl
sinc
rhinovirus
major
caus
common
cold
therefor
among
preval
viru
infect
determin
high
resolut
structur
two
picornavirus
polioviru
type
hogl
et
al
rhinoviru
rossmann
et
al
initi
design
new
type
viral
inhibitor
virus
one
structur
protein
display
narrow
deep
cleft
canyon
encircl
fivefold
vertex
viral
icosahedron
cleft
lead
hydrophob
pocket
surfac
virion
author
suggest
cleft
surround
conserv
amino
acid
residu
spatial
protect
antibodi
might
bind
site
cellular
receptor
hypothesi
confirm
determin
structur
rhinoviru
complex
intercellular
adhes
receptor
molecul
rhinovirus
use
receptor
obviou
idea
use
molecul
prevent
viru
attach
target
cell
integr
membran
glycoprotein
contain
five
extracellular
immunglobulinlik
domain
sinc
rhinovirus
bind
two
aminotermin
domain
solubl
compris
domain
use
competit
experi
protein
produc
chines
hamster
ovari
cell
secret
properli
glycosyl
human
protein
could
inhibit
infect
sever
rhinovirus
vitro
crump
et
al
ohlin
et
al
howev
human
trial
intranas
applic
solubl
prior
viru
challeng
volunt
reduc
symptom
prevent
infect
turner
earli
observ
previous
synthes
rhinoviru
inhibitor
eg
disoxaril
win
bound
hydrophob
pocket
start
develop
drug
prevent
adsorpt
andor
uncoat
viru
mckinlay
et
al
phase
clinic
trial
disoxaril
turn
toxic
new
compound
develop
test
rhinovirus
picornavirus
compound
win
enter
phase
ii
clinic
trial
show
low
activ
wherea
third
gener
agent
pleconaril
fig
evalu
two
extens
trial
consist
individu
symptom
common
cold
began
less
h
begin
treatment
hayden
et
al
studi
show
pleconaril
well
toler
caus
slight
reduct
sever
symptom
fda
give
permiss
use
pleconaril
picovir
antivir
drug
treat
common
cold
sinc
evid
drug
interf
action
contracept
sinc
pleconaril
inhibit
wide
varieti
picornavirus
use
also
treatment
sever
neonat
coxsacki
b
viru
infect
enterovir
hepat
enterovir
meningoenceph
bryant
et
al
far
yet
approv
fda
intranas
appli
pirodavir
fig
anoth
earli
capsidbind
agent
show
prophylact
potenc
phase
ii
trial
volunt
hayden
et
al
howev
compound
unstabl
new
deriv
oral
avail
develop
inhibit
wide
varieti
rhinovirus
well
enterovirus
vitro
far
clinic
trial
compound
publish
barnard
et
al
picornaviru
genom
translat
polyprotein
autocatalyt
cleav
proteas
domain
failur
cleavag
lethal
viru
replic
proteas
would
excel
target
proteas
inhibitor
success
treat
hiv
promis
proteas
inhibitor
also
synthes
hcv
infect
discuss
elsewher
review
sinc
determin
structur
human
rhinoviru
proteas
matthew
et
al
ration
drug
design
activ
hundr
new
compound
antivir
activ
vitro
synthes
seri
peptidomimet
compound
bind
irrevers
activ
site
cystein
proteas
test
properti
vitro
vivo
antivir
activ
far
one
promis
compound
ruprintrivir
fig
dragovich
et
al
test
phase
ii
trial
compound
poorli
solubl
water
therefor
appli
intranas
spray
given
infect
drug
clear
antivir
activ
result
less
encourag
drug
given
h
viru
inocul
hayden
et
al
mode
action
enviroxim
fig
compound
discov
late
turn
differ
inhibitor
describ
enviroxim
seem
inhibit
rna
synthesi
interact
enteroviru
replicas
protein
heinz
vanc
although
enviroxim
could
inhibit
rhinovirus
mani
picornavirus
includ
polioviru
lack
therapeut
activ
clinic
studi
sever
new
compound
synthes
one
inhibit
sever
rhinovirus
enterovirus
far
clinic
trial
report
hamdouchi
et
al
hepat
c
viru
hcv
major
caus
chronic
hepat
liver
cirrhosi
hepatocellular
carcinoma
first
identifi
blood
test
becam
avail
viru
establish
chronic
infect
case
estim
hcv
infect
million
peopl
worldwid
chronic
infect
activ
viru
replic
hcv
resembl
hiv
combin
sever
drug
probabl
requir
effect
manag
erad
viru
current
therapi
hepat
c
polyethylen
glycol
peg
modifi
form
use
combin
ribavirin
fig
moradpour
et
al
although
combin
therapi
quit
effici
limit
signific
toxic
lack
respons
larg
number
patient
fusion
peg
molecul
interferon
result
biolog
activ
drug
longer
halflif
favor
pharmacokinet
ribavirin
broadrang
antivir
agent
mechan
action
still
unclear
believ
inhibit
inosin
monophosph
dehydrogenas
impdh
enzym
catalys
ratelimit
step
gtp
synthesi
lead
decreas
pool
gtp
level
cell
indirectli
lead
suppress
viral
rna
synthesi
tan
et
al
also
suggest
ribavirin
act
rna
viru
mutagen
forc
virus
error
catastroph
crotti
et
al
problem
develop
antihcv
therapeut
includ
persist
viru
genet
divers
gener
replic
host
develop
drugresist
viru
mutant
research
hcv
replic
hamper
lack
reproduc
infecti
cultur
system
smallanim
model
tan
et
al
howev
studi
hcv
replic
develop
new
therapi
consider
advanc
recent
develop
cell
cultur
model
hcv
replicon
system
lohmann
et
al
system
base
stabl
replic
subgenom
select
hcv
rna
propag
effici
human
hepatoma
cell
high
level
replic
depend
cell
cultur
adapt
mutat
aris
sever
nonstructur
protein
replicon
system
allow
product
infecti
viru
particl
hcv
positivesens
rna
genom
belong
famili
flavivirida
tabl
genom
encod
singl
polyprotein
amino
acid
co
posttransl
cleav
sever
site
host
signal
peptidas
two
hcvencod
proteas
result
product
least
three
structur
six
nonstructur
protein
addit
proteas
helicas
polymeras
enzym
code
within
nonstructur
protein
far
proteas
rnadepend
rna
polymeras
major
target
drug
develop
unfortun
mechan
viral
entri
receptor
hcv
still
poorli
understood
would
offer
promis
target
biln
fig
novel
hcv
serin
proteas
inhibitor
great
therapeut
potenti
hcv
replic
lamarr
et
al
small
molecul
biolog
avail
oral
ingest
abil
biln
inhibit
proteas
activ
human
liver
cell
test
use
replicon
system
human
trial
biln
show
promis
result
suppress
viral
load
patient
treat
biln
significantli
greater
ifntreat
patient
fig
anoth
small
molecul
proteas
inhibitor
identifi
structurebas
drug
design
approach
evolv
natur
substrat
inhibitori
effect
polyprotein
process
test
use
hcv
replicon
system
lin
et
al
action
compar
biln
data
suggest
molecul
differ
mechan
inhibit
distinct
drugresist
mutat
identifi
proteas
inhibitor
mutant
resist
biln
remain
fulli
sensit
lin
et
al
merimepodib
oral
administ
small
molecul
inhibitor
impdh
recent
studi
use
replicon
system
demonstr
impdh
inhibitor
enhanc
antivir
activ
ribavirin
vitro
zhou
et
al
result
show
combin
treatment
ribavirin
impdh
inhibitor
increas
replicon
error
rate
data
consist
suggest
ribavirin
act
mutagen
result
phase
ii
clinic
trial
show
tripl
combin
merimepodib
peginterferon
ribavirin
well
toler
led
statist
signific
increas
proport
patient
undetect
level
hepat
c
viru
week
treatment
viramidin
fig
prodrug
ribavirin
convert
adenosin
deaminas
ribavirin
liver
cell
compar
ribavirin
less
uptak
viramidin
red
blood
cell
due
posit
charg
molecul
result
reduct
hematolog
toxic
one
side
effect
ribavirin
phase
ii
clinic
trial
shown
viramidin
may
effect
ribavirin
hepat
c
decreas
patient
risk
develop
anemia
tan
et
al
addit
hcv
dengu
viru
diseas
repres
global
problem
mairuhu
et
al
diseas
alreadi
endem
hundr
countri
estim
caus
million
infect
annual
half
million
case
dengu
hemorrhag
fever
four
serotyp
mosquitotransmit
flaviviru
even
though
primari
infect
one
serotyp
may
mild
febril
diseas
second
infect
often
lead
seriou
hemorrhag
fever
ribavirin
glycyrrhizin
inhibit
dengu
virus
cell
cultur
cranc
et
al
systemat
vivo
studi
ribavirin
encourag
similarli
hcv
viral
proteas
promis
target
structur
dengu
viru
proteas
domain
determin
murthi
et
al
anoth
import
problem
caus
flaviviru
recent
spread
west
nile
viru
northern
america
mosquitotransmit
viru
caus
close
human
case
death
alon
viru
origin
africa
transmit
larg
varieti
mosquito
speci
seriou
case
treat
ribavirin
plu
combin
poor
result
review
gould
fikrig
ebola
viru
first
appear
sever
outbreak
report
africa
sinc
origin
negativestrand
rna
viru
still
obscur
togeth
similar
marburg
viru
ebola
one
contagi
pathogen
virus
known
half
infect
may
fatal
mouseadapt
ebola
viru
use
model
test
antivir
drug
nontox
dose
sadenosyl
homocystein
hydrolas
inhibitor
carbocycl
fig
result
surviv
anim
given
day
infect
bray
et
al
inhibitor
enzym
previous
shown
inhibit
rhabdo
paramyxovirus
de
clercq
one
possibl
lower
concentr
sadenosylhomocystein
cell
drug
interfer
methyl
step
viral
rna
cap
see
hantaan
virus
caus
sever
renal
hemorrhag
syndrom
treat
success
intraven
ribavirin
huggin
et
al
recent
vitro
studi
suggest
ribavirin
caus
error
catastroph
hantaan
viru
rna
replic
severson
et
al
possibl
smallpox
variola
viru
may
becom
avail
bioterrorist
becom
concern
author
mani
countri
sinc
complet
genom
sequenc
mani
poxvirus
avail
would
possibl
reconstruct
variola
viru
previous
use
vaccin
avail
quantiti
requir
vaccin
gener
popul
also
occasion
caus
sever
complic
reason
exist
antivir
drug
poxvirus
especi
variola
reevalu
one
earliest
agent
thiosemicarbazon
deriv
methisazon
marboran
use
success
prophylaxi
smallpox
india
treatment
vaccin
complic
due
side
effect
accept
wider
use
still
may
good
lead
drug
develop
mani
drug
develop
virus
shown
inhibit
replic
vaccinia
viru
includ
agent
affect
nucleotid
metabol
eg
ribavirin
eicar
analogu
inhibit
dna
synthesi
eg
cmethylado
arac
cidofovir
fig
deriv
chpmpc
hdphpmpc
neyt
de
clercq
recent
differ
antivir
agent
test
inhibitori
activ
replic
vitro
sever
poxvirus
cidofovir
ribavirin
may
provid
best
choic
gener
use
case
urgenc
accept
previous
clinic
use
although
differ
purpos
baker
et
al
plan
larg
systemat
effort
look
antismallpox
agent
present
harrison
et
al
virus
synthes
cap
rna
effici
recognis
cellular
ribosom
protein
synthesi
although
virus
picornavirus
use
altern
mechan
enhanc
translat
rna
cap
essenti
virus
involv
sever
enzymat
reaction
rna
triphosphatas
guanylyltransferas
methyltransferas
sever
case
virus
encod
rna
cap
enzym
may
act
mechan
differ
cellular
rna
cap
apparatu
differ
specif
make
attract
target
virusspecif
cap
enzym
best
character
alphaviruslik
superfamili
positivestrand
rna
virus
includ
arthropodborn
alphavirus
distant
rel
rubella
viru
hepat
e
viru
ahola
magden
et
al
ahola
variou
cap
analogu
test
inhibitori
activ
lampio
et
al
although
virus
steal
cap
cellular
rna
describ
influenza
endonucleas
group
posit
neg
strand
rna
virus
possess
cap
enzym
mani
remain
uncharacter
first
exampl
rna
virus
structur
cap
methyltransferas
describ
flaviviru
dengu
egloff
et
al
positivestrand
rna
virus
replic
rna
membranebound
complex
salonen
et
al
therefor
inhibit
membran
associ
could
gener
applic
target
virus
howev
mani
case
mechan
membran
associ
remain
poorli
understood
salonen
et
al
alphavirus
repres
first
exampl
structur
character
membran
bind
middl
replicas
protein
acid
peptid
respons
bind
whole
replic
complex
cytoplasm
side
plasma
membran
endosom
peptid
form
amphipath
alpha
helix
hydrophob
residu
embed
within
fatti
acid
tail
posit
charg
residu
interact
neg
charg
polar
group
phospholipid
lampio
et
al
ahola
antivir
drug
screen
test
last
year
mani
earli
drug
nucleosid
nucleotid
analogu
turn
specif
virus
eg
acyclovir
deriv
modern
virolog
provid
tool
studi
detail
viru
replic
molecular
level
enorm
challeng
caus
appear
hiv
shown
new
drug
develop
scientif
commun
make
concert
effort
solv
detail
viru
replic
cycl
similarli
hiv
replic
hcv
becom
well
character
knowledg
like
allow
deliveri
drug
use
treatment
patient
near
futur
systemat
studi
influenza
hemagglutinin
neuraminidas
protein
sialic
acid
ligand
yield
compound
use
diseas
treatment
prevent
ration
approach
also
use
develop
rhinoviru
inhibitor
almost
year
without
clear
breakthrough
show
inher
difficulti
field
newli
emerg
threaten
virus
anoth
area
activ
target
studi
viru
inhibitor
